Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
This article presents new treatment options, discussing the most important findings from clinical trials and real-world reports, clinical benefits and risks of treatment, as well as efficacy of re …
Trastuzumab (Herceptin) for Metastatic Breast Cancer Treatment
Sep 17, 2025 · Find data from studies on trastuzumab (Herceptin) and metastatic breast cancer treatment.
Treatment of Stage IV (Metastatic) Breast Cancer
Tucatinib (Tukysa), trastuzumab, and the chemo drug capecitabine (this combination can be helpful for cancers that have spread to the brain) Because current treatments are very unlikely …
Phase III Trial Results Suggest a New Standard of Care in Metastatic ...
Jun 25, 2025 · The phase III DESTINY-Breast09 trial evaluated fam-trastuzumab deruxtecan-nxki (T-DXd) plus pertuzumab vs chemotherapy as first-line treatment of patients with metastatic …
Evolving Treatments and Advances in HER2-Positive Breast Cancer
Mar 20, 2025 · HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and …
Updates in Treatment of HER2-positive Metastatic Breast Cancer
Nov 9, 2024 · The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal …
Which Tx Combo Is Best for HER2+ Breast Cancer? - Medscape
Jun 6, 2025 · The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to …
What Herceptin® (trastuzumab) Treats | HER2+ Metastatic Breast Cancer
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, …
Enhertu Plus Pertuzumab Approved for First-Line HER2+ Breast Cancer
6 days ago · The FDA approved Enhertu with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
T-DXd Plus Pertuzumab Outperforms Standard of Care for First …
Jun 2, 2025 · In 2019, T-DXd showed striking improvements in progression free survival among patients with metastatic HER2-positive breast cancer who had already received up to six lines …